Sugi Predict

Sugi Predict / Compounds / SCHEMBL7233158

SCHEMBL7233158

SCHEMBL7233158

CCOC(=O)C(C)Oc1ccc(-c2nc(-c3ccc(C)cc3C)nc(-c3ccc(C)cc3C)n2)c(O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ ALDH2 P05091 1/20 0.43
▸ KMT2A Q03164 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 3/20 0.37
▸ EPHX2 P34913 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ GAA P10253 2/20 0.36
▸ POLB P06746 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29517028 0.91 LMNA (0.52) LMNAL3MBTL1ALDH2KMT2ASMN1; SMN2
SCHEMBL5038880 0.91 LMNA (0.52) LMNAL3MBTL1ALDH2KMT2ASMN1; SMN2
SCHEMBL8909484 0.89 LMNA (0.44) LMNAL3MBTL1ALDH2KMT2ASMN1; SMN2
SCHEMBL25375164 0.89 ALDH2 (0.44) L3MBTL1ALDH2KMT2ASMN1; SMN2MEN1
SCHEMBL27168219 0.86 TDP1 (0.51) LMNAALDH2KMT2ASMN1; SMN2MEN1
SCHEMBL10034102 0.85 LMNA (0.47) LMNAL3MBTL1ALDH2KMT2ASMN1; SMN2
SCHEMBL7971455 0.85 LMNA (0.47) LMNAL3MBTL1ALDH2KMT2ASMN1; SMN2
SCHEMBL15721391 0.83 LMNA (0.45) LMNAL3MBTL1ALDH2KMT2ASMN1; SMN2
SCHEMBL7051321 0.83 L3MBTL1 (0.54) LMNAL3MBTL1ALDH2KMT2ASMN1; SMN2
SCHEMBL13597427 0.82 ALDH2 (0.47) LMNAL3MBTL1ALDH2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653484-B2 Triazine, benzotriazole, or benzophenone-type stabilizers conjugated to polyoxyalkylene groups; use as ultraviolet radiation absorbers in photographic materials CIBA SPECIALTY CHEMICALS CORPORATION 2003-11-25 — — US disclosed
US-20020094320-A1 Polyoxyalkylene substituted and bridged benzotriazole derivatives TOAN VIEN VAN (CH) 2002-07-18 — — US disclosed
US-6369267-B1 RADIATION RESISTANCE TO ULTRAVIOLET RADIATION CIBA SPECIALTY CHEMICALS CORPORATION 2002-04-09 — — US disclosed
EP-0912531-A1 POLYOXYALKENE SUBSTITUTED AND BRIDGED TRIAZINE, BENZOTRIAZOLE AND BENZOPHENONE DERIVATIVES AS UV ABSORBERS Ciba SC Holding AG (CH) 1999-05-06 — — EP disclosed
WO-1998003489-A1 POLYOXYALKENE SUBSTITUTED AND BRIDGED TRIAZINE, BENZOTRIAZOLE AND BENZOPHENONE DERIVATIVES AS UV ABSORBERS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094320-A1 Polyoxyalkylene substituted and bridged benzotriazole derivatives TPT1, TYR, TERB1 LMNA 2729/4885L3MBTL1 1598/4885ALDH2 2312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.